回答: 他最起嗎還有一次機會.我沒有他. 由 xiamai 於 2007-04-12 09:23:00 其實要把握機構對於他的態度是不難的,但是還有沒有你說的大機會,誰也不知道。
我為什麽在周末推薦買DNDN,因為周五的時候股價再次攀升到18以上(第一天是從18往下紮的最低12),這個時候是明確的作多信號,MM一定要再創新高,而且一般來說都是至少30%-50%的幅度
Dendreon (DNDN) Surges Higher 04-05-2007 01:19:05 PM Dendreon Corp. (Nasdaq: DNDN) is seeing significant upside action (+15%) this afternoon on heavy volume, bringing its 52-week high of $18.05 in play. A short squeeze is suspected.
On March 29, in a surprise move an FDA panel backed the company's PROVENGE for prostate cancer. The Company anticipates a decision from the FDA on PROVENGE by May 15, 2007.
周一如期上漲,周二盤前就已經瘋狂張到26了,(高總不想馬後炮說是盤前就跑了),18到26就一天時間,40%了,不跑,還等什麽呢?但是機構也需要出來放煙霧彈,果然下午MDB置疑FDA會對DNDN的panel推薦真的十分留意,他們為什麽機構服務?不知道,但是一定是。
MDB Capital questions whether the FDA will heed the advice of the advisory panel on Dendreon (DNDN) 04-10-2007 02:32:49 PM MDB Capital comments on Dendreon Corp. (Nasdaq: DNDN), questioning whether the FDA will heed the advice of the advisory panel. The firm said, "The recent vote (13 to 4) in favor of Provenge approval by the cellular, tissue and gene therapy advisory panel was a surprise. We believe the FDA will think hard about this one and is probably in a dilemma of sorts. While the FDA normally heeds the decision of its advisory panel, this particular case may not be clear cut." The firm maintains their Neutral rating.
緊接著,昨天早上JMP出來再次downgrade,DNDN股價再次大幅度下滑
JMP Securities downgrades Dendreon (DNDN) to Market Outperform 04-11-2007 09:12:31 AM JMP Securities downgrades momentum mover Dendreon (Nasdaq: DNDN) from Strong Buy to Market Outperform.
昨日盤後又有大量的DNDN如何價值甚至200的豪言,高總實在看不下去了,所以今日在股價低開高走之後,高總在大千預警:DNDN也許就是當年的IPIX。
不要被表象迷惑,5.15之前的表演就是MM的表演。這個時候技術麵更為重要。
|